In 2024, Siegfried continued its trajectory of profitable growth, more than offsetting substantial headwinds. Read the media release to learn more: https://lnkd.in/dFUrwURs #mediarelease #annualresults #profitablegrowth
Siegfried
Arzneimittelherstellung
Zofingen, Aargau 33.710 Follower:innen
Expect more
Info
Siegfried is a leading CDMO with 13 production sites on three continents. With our longstanding pharmaceutical and chemical experience, we are taking your innovations to industrial scale. Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services.
- Website
-
http://www.siegfried.ch
Externer Link zu Siegfried
- Branche
- Arzneimittelherstellung
- Größe
- 1.001–5.000 Beschäftigte
- Hauptsitz
- Zofingen, Aargau
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 1873
- Spezialgebiete
- Formulation Development, Analytical Development, Solid Dosage Forms, Parenterals (vials, ampoules, cartridges, syringes), Ophtalmics (liquids and semisolids), API, Active Pharmaceutical Ingredient, Exclusive Synthesis, High Potency, Intermediates, Sterile Filling, biologics finished dosage forms und spray drying
Orte
Beschäftigte von Siegfried
Updates
-
Quality by Design (QbD), is an important tool for ensuring the pharmaceuticals taken by patients are consistently safe. Read the blog from Maja Kandziora on how leveraging model-based QbD allows for fast process optimization, and better control over quality: https://lnkd.in/dPrSqieP
Quality Engineered: The power of QbD
content.siegfried.ch
-
Women and girls play a critical role in science and technology. Today on the UN's "International Day of Women and Girls in Science," we asked Siegfried employees share their advice to young women pursuing careers in science. #diversityinstem
-
Thank you Juergen Roos from the entire Siegfried team! 👏 ❤️
After almost six years, today marks Juergen Roos final working day at Siegfried. During our time together on the Executive Committee, I came to know Jürgen as a knowledgeable, motivated, and passionate individual. With his scientific expertise, he took Siegfried's R&D operations to the next level, building the foundation for development excellence which is one of the cornerstones of our EVOLVE+ strategy. I wish him all the best for the future and thank him for his many contributions.
-
-
Maximizing speed to clinical is crucial in drug development. In our latest article, Jennifer DePolo from the Siegfried Acceleration Hub dives into success factors that will help start a program on the road to speedy and successful commercialization. Read the full article here: https://lnkd.in/dkCtxTaE
-
-
Global Head of Business Excellence and Corporate Projects, Peter Kienholz was invited to contribute his views on the key issues shaping development and manufacturing of small-molecule. Read the article to learn more.
New #DCAT #ValueChainInsights Article: What are the key issues shaping the market for small-molecule drugs and related trends in manufacturing? An industry roundtable of senior executives share their perspectives on what is driving the market. Read it here: https://lnkd.in/eQj4fkY9
-
-
Members of our leadership team joined the Annual Dinner in Siegfried Nantong to celebrate many achievements: an outstanding safety record, operational excellence and improvements in OTIF.
I recently had the pleasure of visiting Siegfried Nantong with our CEO Marcel Imwinkelried and our chairman Andreas Casutt, where I joined colleagues in celebrating their incredible achievements at their Annual Dinner. It was inspiring to reflect on the team's outstanding safety record, impressive operational efficiency, and notable improvements in OTIF. A heartfelt thank you to all Siegfried Nantong colleagues for the warm hospitality, meaningful conversations, and this truly insightful experience. Your hard work and commitment are valued and appreciated. #CDMO
-
-
At Siegfried Evionnaz, we’re proud to take concrete steps toward reducing our carbon footprint and supporting sustainable energy. Our newly installed solar panels have generated their first kWh of energy. With 810 photovoltaic panels, they will produce 280 MWh annually—enough to power 60 households. By mid-2025, two more buildings will be equipped with solar panels, further boosting our clean energy production. #sustainabilityleader #solarenergy #cleanenergy
-
-
In recent years, the molecules entering the pharmaceutical pipeline have become ever more complex. The increased difficulties involved in turning these molecules into effective medicines add to the risks of development, with a knock-on effect on meeting timelines and hitting milestones. Read the blog by Klaus Stingl to learn how to navigate these challenges: https://lnkd.in/dNb34-R7
-
-
At Siegfried, we are committed to empowering women and supporting the next generation of professionals. To help inspire future industry leaders, we were pleased to welcome a group of young women at our headquarters in Zofingen to help them explore career paths in the life sciences industry.
This week, we had the pleasure of hosting a Connect event at our Zofingen site through PSI Paul Scherrer Institut program, welcoming a group of talented young women eager to explore career opportunities in the pharmaceutical industry. The day began with inspiring speeches from our colleagues, Dorothea Ledergerber and Maja Kandziora 🗣️ followed by engaging roundtable discussions 💬 where students could ask questions and exchange ideas about careers, challenges, and opportunities in the field. 🔬 We wrapped up with an exclusive tour of our labs and production site, offering a firsthand look at how we combine innovation and precision to bring pharmaceutical solutions to life. 👏 A big thank you to Dorothea and Maja for their time and insights, to Corinne Bühler and Luigi Mangieri for the tours! Also, a big thank you to everyone at PSI who contributed to this event. Programs like Connect are a testament to Siegfried’s commitment to empowering women and supporting the next generation of professionals.
-